Teva Acquires Emalex for Ecopipam, D1 Receptor Drug for Pediatric Tourette Syndrome
Teva acquires Emalex for ecopipam, a D1 receptor drug with Phase 3 data showing efficacy in pediatric Tourette syndrome,...
No videos found.
Apollo Therapeutics Appoints Timothy Walbert as Chairman
Apollo Therapeutics appoints Timothy Walbert as chairman, signaling a shift toward commercial strategy for the biotech company's university-sourced pipeline.
Alembic Acquires NUVESSA for Bacterial Vaginosis Treatment
Alembic acquires NUVESSA for bacterial vaginosis treatment, expanding its women's health portfolio with a single-dose metronidazole gel option.
Cartesian, WestGene Partner on In Vivo CAR-T for Myasthenia Gravis
Cartesian and WestGene partner on in vivo CAR-T for myasthenia gravis, combining mRNA payload with lipid nanoparticle delivery in...
Disc Medicine’s FDA Meeting Just Reset the Bitopertin Timeline: What the Street Should Actually Be Watching
After a Feb 2026 CRL rejection, Disc Medicine secured FDA alignment on a Phase 3 pathway for bitopertin in...
Optimi Health Secures Ibogaine Supply for U.S. Clinical Trials
Optimi Health secures ibogaine supply for U.S. clinical trials, leveraging Canadian manufacturing to address a research bottleneck amid accelerated...
Tonix’s Second GPO Agreement for TONMYA Signals a Market Access Inflection Point for Fibromyalgia Coverage
Tonix Pharmaceuticals secured a second GPO agreement June 1, 2026, expanding TONMYA commercial coverage to ~52M U.S. lives—10 months...
Perrigo CEO Patrick Lockwood-Taylor Out Over Conduct Violation
Perrigo CEO Patrick Lockwood-Taylor exits after three years due to conduct violation. Board names interim successor and reaffirms 2026...
GSK partners with Engitix on liver fibrosis regression targets in £44.5M deal
GSK partners with Engitix on liver fibrosis regression targets in £44.5M deal focused on activating resolution pathways.
GNI Group to Acquire Ayumi Pharmaceutical Holdings for ¥44.8 Billion
GNI Group to acquire Ayumi Pharmaceutical Holdings for ¥44.8 billion, gaining Calonal® acetaminophen dominance and Japanese distribution infrastructure.